This review summarizes the basic and clinical pharmacology of emerging antiarrhythmic drugs for atrial fibrillation, including vernakalant, dronedarone, and ranolazine.
Novel atrial-selective agents may improve AF therapy safety; leaves open clinical validation in randomized trials.
Atrial fibrillation is a complex arrhythmia that is difficult to treat with conventional antiarrhythmic agents. Novel pharmacological approaches are in progress focused on the development of agents with selective affinity to ion channels predominately involved in the atrium. In parallel, research efforts have been focused on the development of agents targeting to modification of those pathways and molecular mediators which are involved in the propagation and maintenance of atrial fibrillation ( AF ). In this review, we focus on the basic and clinical pharmacology of new and emerging antiarrhythmic drugs such as vernakalant, dronedarone, and ranolazine, whereas we briefly comment on the future directions of antiarrhythmic therapy in AF . Answer questions and earn CME: https://wileyhealthlearning.com/Activity2/4469486/Activity.aspx
No takes yet. Share an insight, caveat, or question.
Fragakis et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: